PRGONYSEPharmaceutical PreparationsFiscal year ends December 31
PERRIGO Co plc
Financials through Q2 FY2026, quarter ended Jun 27, 2026Last filing: 10-Q on Aug 5, 2026
$16.09−0.54 (-3.25%)
Close on Oct 19, 2026
- Market cap
- $2.25B
- P/E (TTM)
- –
- Dividend yield
- 7.21%
Margins
Share of revenue, fiscal years 2013 to 2025
Gross margin
35.1%−1.4 pts over 5 years
Operating margin
-26.4%−32.9 pts over 5 years
Net margin
-33.5%−29.5 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -2.8% | -1.5% | +0.8% | +0.1% | |
| Gross profit | -3.1% | +0.9% | -0.0% | -1.0% | |
| Free cash flow | -40.7% | -11.7% | -20.8% | -14.8% | |
| Dividend per share | +5.5% | +3.7% | +5.2% | +9.7% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2015 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 1.4% | -2.8% | -39.3% | |
| Return on assets | 0.8% | -1.4% | -15.7% | |
| Current ratio | 1.85 | 2.27 | 2.76 | |
| Debt to equity | 0.56 | 0.63 | 1.24 | |
| Net debt to EBITDA | 5.63× | 4.51× | -3.96× | |
| Inventory turnover | 3.3× | 2.6× | 2.5× | |
| Capex to revenue | 3.2% | 4.2% | 2.2% | |
| Diluted shares | 140M | 137M | 139M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Perrigo generated $1.47B from operations and spent $1.30B on capital expenditure, dividends and share buybacks. 43% of that went back into the business.
Generated
$1.47B
Used
$1.30B
Capital expenditure$561.90M43%Dividends$733.50M57%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-33.5%
×Asset turnover0.47×
×Equity multiplier2.51×
=Return on equity, FY2025-39.3%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -33.5% | 0.47× | 2.51× | -39.3% |
| FY2024 | -3.9% | 0.43× | 2.25× | -3.8% |
| FY2023 | -0.3% | 0.43× | 2.27× | -0.3% |
| FY2022 | -3.2% | 0.42× | 2.15× | -2.8% |
| FY2021 | -1.7% | 0.38× | 2.03× | -1.3% |
| FY2020 | -4.0% | 0.36× | 1.99× | -2.8% |
| FY2019 | 3.8% | 0.35× | 1.94× | 2.5% |
| FY2018 | 2.8% | 0.42× | 1.91× | 2.2% |
| FY2015 | 3.2% | 0.25× | 1.72× | 1.4% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero-$1.43B
- Cash generatingOperating cash flow above zero$238.50M
- Return on assets improvedROA up on the prior year-1.6% → -14.8%
- Earnings backed by cashOperating cash flow above net income$238.50M vs -$1.43B
- Less leverageLong-term debt to assets fell37.1% → 42.2%
- Better liquidityCurrent ratio rose2.38 → 2.76
- No dilutionShare count did not rise137M → 139M
- Gross margin improvedGross margin up on the prior year35.27% → 35.14%
- More efficientAsset turnover rose0.40 → 0.44